A citizen petition asking FDA to cut allowable levels of a growth drug used in most U.S. pork and a large share of U.S. beef sat unanswered for twelve years. A second, emergency petition filed in 2020 asking FDA to suspend the drug's approval during pandemic-era slaughterhouse disruptions got the same silence. It took four advocacy organizations suing FDA in federal court to get a response at all — and when the agency finally answered, it said no.
The drug is ractopamine, a beta-agonist fed to swine, cattle, and turkeys in the final weeks before slaughter to increase leanness and feed efficiency. FDA first approved it for swine on December 22, 1999, and the drug, sold under the brand name Paylean, is still governed today by 21 CFR 558.500, which permits it in finishing swine at 4.5 to 9.0 grams per ton, in confined beef cattle at 8.2 to 24.6 grams per ton for the last 28 to 42 days on feed, and in finishing turkeys at 4.6 to 11.8 grams per ton — with an explicit bar on using it in any animal intended for breeding.
On March 26, 2024, the Animal Legal Defense Fund, the Center for Biological Diversity, the Center for Food Safety, and the Food Animal Concerns Trust sued FDA in the U.S. District Court for the District of Columbia. Their claim wasn't that ractopamine is unsafe — it was narrower and, under the Administrative Procedure Act, harder for FDA to simply ignore: that the agency had gone more than a decade without substantively responding to their 2012 petition, and years without responding to the 2020 one, and that federal law requires an agency to actually decide on a rulemaking petition within a reasonable time. FDA did eventually respond, around February 2025, according to the petitioning groups' own account of the agency's letter — declining to find that the drug is unsafe for the animals given it. Unsatisfied, the same four groups filed a new petition on April 29, 2025, asking FDA to reconsider that response and either reduce allowable ractopamine levels or withdraw its approval outright. As of this writing, that petition is still pending.
While that fight was working through federal court, the practical stakes of the same disagreement were playing out at the border. On May 27, 2024, Chinese customs authorities suspended meat imports from two specific U.S. facilities — the JBS-owned Swift Beef Company plant in Greeley, Colorado, and the Cool Port Oakland cold-storage facility near the Port of Oakland — after detecting ractopamine residue in shipments, according to reporting citing USDA's Food Safety and Inspection Service. It's a narrow, facility-specific action, not a blanket ban on U.S. meat, but it's a concrete illustration of what the international disagreement over this drug actually costs in practice: individual shipments and individual plants losing market access over a substance the exporting country's own regulator has approved for decades.
That disagreement isn't new, and it isn't just the U.S. against everyone else. In July 2012, the Codex Alimentarius Commission — the joint FAO/WHO body that sets international food-safety reference standards — voted to adopt maximum residue limits for ractopamine in beef and pork. The vote was 69 in favor, 67 against, with seven abstentions: one of the narrowest, most contested votes in Codex's history, and a real signal that the international scientific consensus on this drug is genuinely split, not lopsided. The European Union has banned beta-agonists like ractopamine from livestock production outright since Council Directive 96/22/EC took effect on July 1, 1997 — years before Codex ever took up the question, and on a categorical basis rather than a residue-limit basis. China's restrictions work differently again: rather than a blanket prohibition written into law the way the EU's is, China enforces a zero-tolerance import standard through customs detection, which is what triggered the Colorado and Oakland suspensions.
The health-research picture behind all of this centers on ractopamine's mechanism rather than a single flashpoint study. As a beta-agonist, it works by binding to the same class of receptors that adrenaline activates, which is the basis for both its effectiveness as a growth promoter and the animal-welfare and cardiovascular concerns raised in the citizen petitions and in the FDA lawsuit — concerns about stress, mobility problems, and cardiac strain in treated animals, and about low-level residue exposure in the people who eat the meat. FDA's own position, reaffirmed in its 2025 response to the petitioners, is that current residue limits are adequately protective; the petitioning groups argue FDA hasn't meaningfully revisited that position with current evidence. Neither side disputes that this is fundamentally a live, unresolved disagreement rather than a settled question either way.
On the label, there's nothing to look for, because there's nothing there. Ractopamine is a feed additive, not a food additive — it's metabolized out of the animal well before slaughter under FDA's own withdrawal-period rules, and U.S. law doesn't require it to be disclosed on retail meat packaging the way an ingredient would be. The only way a shopper can currently avoid it by reading a label is to look for a voluntary "ractopamine-free" certification, which some U.S. producers carry specifically because major export markets, including China and the EU, require it as a condition of doing business with them — meaning the same claim that's invisible on most domestic packaging is often required paperwork the moment that same product crosses a border.
None of this resolves into a verdict, and that's deliberate. A drug the U.S. has approved for a quarter-century, an international standard-setting body that adopted it by two votes, a European ban that predates the international standard entirely, and a federal lawsuit that only just forced an actual FDA response — four processes, running on four different tracks, none of them pointing the same direction. PurityIQ doesn't try to collapse that into a score. It shows you, at the shelf, what's actually on the record for a product you're scanning — the FDA tolerance, the litigation history, the international divergence — cited to the source, not to an advocacy group's summary of it. You see the record. You decide.
As of September 2026, ractopamine remains an approved feed additive under 21 CFR 558.500, the April 2025 reconsideration petition remains pending before FDA, and the drug remains prohibited from livestock production in the European Union under Council Directive 96/22/EC.
Sources
21 CFR 558.500 — Ractopamine (eCFR) — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-558/subpart-B/section-558.500
Federal Register, New Animal Drugs for Use in Animal Feeds; Ractopamine Hydrochloride, 65 FR 4111 (Jan. 26, 2000) — https://www.federalregister.gov/documents/2000/01/26/00-1789/new-animal-drugs-for-use-in-animal-feeds-ractopamine-hydrochloride
Animal Legal Defense Fund, Case Summary — Animal Legal Defense Fund et al. v. FDA et al. (D.D.C., filed Mar. 26, 2024) — https://aldf.org/case/challenging-fdas-unreasonable-delay-in-responding-to-petition-to-limit-use-or-withdraw-approval-of-ractopamine/
Animal Legal Defense Fund, "Petition Urges FDA to Reconsider Decision Not to Ban Controversial Drug Ractopamine" (reporting the Apr. 29, 2025 reconsideration petition and FDA's prior response) — https://aldf.org/article/petition-urges-fda-to-reconsider-decision-not-to-ban-controversial-drug-ractopamine/
Center for Food Safety, "Lawsuit Filed Demanding FDA Respond to Petitions Seeking to Ban Ractopamine" — https://centerforfoodsafety.org/press-releases/6904/lawsuit-filed-demanding-fda-respond-to-petitions-seeking-to-ban-ractopamine
DTN Progressive Farmer, "China Stops Beef Exports From JBS Meat Plant in Colorado After Ractopamine Found" (reporting USDA-FSIS confirmation, May 27, 2024 action) — https://www.dtnpf.com/agriculture/web/ag/news/business-inputs/article/2024/05/29/china-stops-beef-exports-jbs-meat
WHO, "UN food safety body sets limits on veterinary growth promoting drug" (Codex Alimentarius Commission, July 2012, vote 69-67-7) — https://www.who.int/news/item/06-07-2012-un-food-safety-body-sets-limits-on-veterinary-growth-promoting-drug
Council Directive 96/22/EC of 29 April 1996 (beta-agonist and hormone prohibition in stockfarming, effective July 1, 1997) — https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A31996L0022